Whitehawk Therapeutics (WHWK) director receives 38,040 stock options grant

Rhea-AI Filing Summary

Whitehawk Therapeutics director Baiteng Zhao received a grant of stock options as compensation. On the grant date, Zhao was awarded options for 38,040 shares of common stock at an exercise price of $4.16 per share, expiring on June 12, 2036. All options vest 100% after about one year or just before the next annual stockholder meeting, as long as Zhao continues serving the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Zhao Baiteng

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	38,040	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 38,040 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 38,040 options Exercise price: $4.16 per share Expiration date: June 12, 2036 +3 more

6 metrics

Options granted 38,040 options Stock option grant to director Baiteng Zhao

Exercise price $4.16 per share Stock option strike price for the grant

Expiration date June 12, 2036 Option term end for granted options

Underlying shares 38,040 shares Common stock underlying the granted options

Post-grant derivative holdings 38,040 options Total options held following the transaction

Vesting percentage 100% cliff vest Vests in full after one year or before next annual meeting

Key Terms

Stock Option (right to buy), exercise price, 2021 Equity Incentive Plan, Service Provider, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "4.1600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2021 Equity Incentive Plan financial

"as defined in the Issuer's 2021 Equity Incentive Plan"

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

vest financial

"one hundred percent (100%) of the shares subject to the option shall vest"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zhao Baiteng

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.16	06/12/2026		A		38,040		(1)	06/12/2036	Common Stock	38,040	$0	38,040	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

	/s/ Stephen Rodin, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Whitehawk Therapeutics (WHWK) report for Baiteng Zhao?

Whitehawk Therapeutics reported that director Baiteng Zhao received a grant of 38,040 stock options. These options give the right to buy common shares at $4.16 each as part of equity compensation, rather than an open-market purchase or sale.

What are the key terms of Baiteng Zhao’s stock option grant at Whitehawk (WHWK)?

Baiteng Zhao’s grant covers 38,040 stock options with an exercise price of $4.16 per share and an expiration date of June 12, 2036. Each option relates to one share of Whitehawk Therapeutics common stock under the company’s equity incentive plan.

When do Baiteng Zhao’s Whitehawk (WHWK) stock options vest?

The options vest 100% on the earlier of one year after the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting. Vesting requires Zhao to continue as a service provider through the applicable vesting date.

Is Baiteng Zhao’s Form 4 transaction in WHWK stock a market buy or sell?

The Form 4 shows a grant of stock options, not a market buy or sell. The transaction is coded “A” for a grant or award acquisition, with a zero-dollar transaction price and a $4.16 per share exercise price for future potential share purchases.

How many Whitehawk (WHWK) derivative securities does Baiteng Zhao hold after this grant?

After this reported grant, Baiteng Zhao holds 38,040 derivative securities in the form of stock options. Each option is exercisable into one share of Whitehawk Therapeutics common stock, subject to the vesting conditions described in the equity incentive plan footnote.